Wilmington Trust’s Novo Nordisk NVO Stock Holding History

Wilmington Trust’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$2.66M	Sell	115,290 -262	-0.2%	-$5.79K	0.04%	222
2014 Q1	$2.64M	Buy	115,552 +1,042	+0.9%	+$22.2K	0.05%	216
2013 Q4	$2.12M	Buy	114,510 +1,030	+0.9%	+$17.9K	0.04%	240
2013 Q3	$1.92M	Sell	113,480 -130	-0.1%	-$2.19K	0.03%	245
2013 Q2	$1.76M	Buy	+113,610	New	+$1.89M	0.04%	245

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Wilmington Trust's NVO Position: Q2 2014 in Review

Wilmington Trust reduced its Novo Nordisk (NVO) stake by 0.23% in Q2 2014, selling an estimated $5.79K and leaving 115,290 shares worth $2.66M. The position accounts for 0.04% of the portfolio, ranked #222.

Wilmington Trust first reported a position in NVO in Q2 2013 and has held it in 5 quarters since. 473 funds tracked by Wall St. Rank hold NVO as of Q2 2014.

Wilmington Trust held 115,290 shares of Novo Nordisk worth $2.66M as of Q2 2014.
Wilmington Trust sold 262 Novo Nordisk shares in Q2 2014, an estimated $5.79K.
Novo Nordisk made up 0.04% of Wilmington Trust's portfolio in Q2 2014, its #222 holding.
Wilmington Trust first reported a position in Novo Nordisk in Q2 2013 and has held it in 5 quarters since.
473 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2014.

Based on Wilmington Trust's 13F filing for Q2 2014, filed 13 Aug 2014.